

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effect of propolis supplementation in reducing pain in patients with Endometriosis

Protocol summary

Study aim

Evaluation of the effect of propolis in reducing pain of endometriosis patients

Design

Clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 40 endometriosis patients. For randomization, permutation block method was used using the site www.randomization.com.

Settings and conduct

The study group are outpatients who use the medicine at home for 4 months. Patients will be collected from Imam Reza Hospital (endometriosis clinic). This clinical trial has a parallel, blinded (patients and interventionists) and randomized control group. The VAS score of the patients is evaluated at the beginning and 4 months after taking the drug or Darnama, and a statistical comparison is made before and after the administration of the drug and between the intervention groups.

Participants/Inclusion and exclusion criteria

Inclusion criteria: having endometriosis with pain. Age between 20 to 45 years. BMI between 18.5 to 27.5. Treated with a standard progesterone-only regimen. Not using NSAIDs to reduce pain. Not using food supplements. Informed consent to participate in the study. Exclusion criteria: allergy to propolis. Suffering from physical and mental illnesses. Use of hormonal methods in the last 3 months. Pregnancy or breastfeeding in the last 3 months.

Intervention groups

Intervention group: Propolis tablets 500 mg twice a day for 4 months along with standard hormonal treatment. Control group: standard treatment (progesterone drugs) along with placebo tablets twice a day for 4 months..

Main outcome variables

Endometriosis pain based on visual analog scale (VAS)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20141230020486N5**
Registration date: **2023-10-14, 1402/07/22**
Registration timing: **prospective**

Last update: **2023-10-14, 1402/07/22**

Update count: **0**

Registration date

2023-10-14, 1402/07/22

Registrant information

Name

Lelli Hafizi

Name of organization / entity

Mashhad University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 51 3802 2608

Email address

hafizil@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-10-23, 1402/08/01

Expected recruitment end date

2024-05-21, 1403/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of propolis supplementation in reducing pain in patients with Endometriosis

Public title

Effect of propolis in pain of Endometriosis

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

All patients with a definite diagnosis of endometriosis by imaging and have pain due to endometriosis
Age between 20-45 years old
Use of standard progesterone hormone treatments
Not using NSAID medications
Not refer for infertility treatment
BMI between 18.5 to 27.5
Not taking food supplements
Obtaining the patient's informed consent

Exclusion criteria:

Use of hormonal contraception and IUD during the last 3 months
Pregnancy or breastfeeding in the last 3 months
The presence of any physical and mental disease
Drug sensitivity to propolis

Age

From **20 years** old to **45 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data and Safety Monitoring Board

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization is according to the block method with various block sizes. A random chain of two groups includes treatment (T) and control (C) with a ratio of 1:1 in blocks of size 4 and 6 (7 blocks of 4 and 2 blocks of 6) with the help of www.sealedenvelope.com for 40 volunteers. Also, a 4-digit personal ID is created for each volunteer. To hide the random allocation, boxes of the same shape are used for the drug and placebo, and these boxes correspond to the random sequence of T and C with the drug or placebo, the row number 1 to 40 and the ID code are recorded on it. The steps of preparation and arrangement of the random sequence are only at the disposal of the epidemiologist of the study. The number box placed is provided to the admissions officer of the applicants. When every candidate enters the study, the box corresponding to the candidate's number is provided to him.

Blinding (investigator's opinion)

Double blinded

Blinding description

All the study subjects, including the patients, the attending physician, and the project manager, are unaware of the allocation of patients to groups and the medicine they receive, and only the epidemiologist (responsible for randomization and final analysis of the

data) is aware of the allocation method. The epidemiologist is neither involved in the prescription nor in the evaluation of the treatment and is only responsible for maintaining the codes and providing the numbered boxes containing the drug or placebo to the attending physician. On the boxes, only rows number 1 to 40 and the ID code are recorded, and the propolis or placebo tablets inside the box are exactly the same shape, size, and color. Therefore, it is not possible to identify the drug from the placebo for the patients, the attending physician, and the project manager. After taking the drug or placebo for 4 months, the patient is evaluated in the hospital clinic by the attending physician who does not know that he has received the drug or placebo and only knows about the ID code. Finally, the attending physician gives the evaluation results to the epidemiologist based on the code.

Placebo

Used

Assignment

Parallel

Other design features**Secondary ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Mashhad University of Medical Sciences

Street address

Vice Chancellor for Research and Technology, Third floor of Ghoreshi building, Next to Hoveyze Cinema, Daneshgah Street, Mashhad

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Approval date

2023-05-22, 1402/03/01

Ethics committee reference number

IR.MUMS.IRH.REC.1402.061

Health conditions studied**1****Description of health condition studied**

Endometriosis of pelvic peritoneum

ICD-10 code

N80.3

ICD-10 code description

Endometriosis of pelvic peritoneum

2

Description of health condition studied

Endometriosis of rectovaginal septum and vagina

ICD-10 code

N80.4

ICD-10 code description

Endometriosis of rectovaginal septum and vagina

Primary outcomes

1

Description

Endometriosis pain

Timepoint

Before the intervention and 4months after the intervention

Method of measurement

Visual Analogue Scale (VAS)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: standard treatment (progesterone drugs) along with propolis tablets 500 mg twice a day for 4 months. These tablets are made by the pharmaceutical laboratory of the Mashhad Faculty of Pharmacy and look exactly like placebo tablets.

Category

Treatment - Drugs

2

Description

Control group: standard treatment (progesterone drugs) along with placebo tablets twice a day for 4 months. These tablets are made by the pharmaceutical laboratory of the Mashhad Faculty of Pharmacy and look exactly like propolis tablets.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Reza Hospital

Full name of responsible person

Leili Hafizi

Street address

Ibn Sina Street, Imam Reza Hospital Square, Imam Reza Educational Research and Treatment Center, Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3854 3031

Email

hafizil@mums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Majid Ghayour Mobarhan

Street address

Vice Chancellor for Research and Technology, third floor of Ghoreishi building, next to Hoveyzeh Cinema, University Street, Mashhad

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Phone

+98 51 3841 1538

Email

GhayourM@mums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Leili Hafizi

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street addressEbnasina Street, Imam Reza Hospital, Gynecology
Department**City**

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3802 2608

Fax

+98 51 3852 5305

Email

hafizil@mums.ac.ir

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Emam Reza Sq, Ebne-sina Ave, Emam Reza hospital

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3802 2608

Fax**Email**

hafizil@mums.ac.ir

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Dr Leili Hafizi

Position

Associated professor

Latest degree

Specialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Emam Reza Sq. Ebne-sina Ave, Emam Reza hospital

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3802 2608

Fax**Email**

hafizil@mums.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Dr Leili Hafizi

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study ReportUndecided - It is not yet known if there will be a plan to
make this available**Analytic Code**Undecided - It is not yet known if there will be a plan to
make this available**Data Dictionary**Undecided - It is not yet known if there will be a plan to
make this available**Title and more details about the data/document**All data is potentially shareable after unidentifiable
individuals**When the data will become available and for how long**

Starting 6 months after publication

To whom data/document is available

People working in academic institutions

Under which criteria data/document could be used

Mention the source

From where data/document is obtainableDr. Lili Hafizi Email: hafizil@mums.ac.ir Phone:
09153107633**What processes are involved for a request to access data/document**

Reply to email within a maximum of one week

Comments